Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients
BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.38603.656076.63 (Published 13 October 2005) Cite this as: BMJ 2005;331:869Data supplement
[Posted as supplied by author]
Appendix: examples of calculation of the risk score
Example 1 is a woman with stable angina aged 65, ejection fraction 55%, white blood cell count 6 giga/l, blood glucose 100 mg/dl (multiply by 0.0555 for mmol/l), serum creatinine 1.25 mg/dl (multiply by 88.4 for μmol/L) who is using one anti-anginal drug and a statin, and has never had a coronary angiogram. The other risk factors in Table 1 are absent. Using the coefficients in the table multiplied by 10, the score contributions are [(65-60)/10]´ 0.55´ 10 or 2.75 for age, [(60-55)/5]´ 0.17´ 10 or 1.7 for ejection fraction, and (6-5)´ 0.068´ 10 or 0.68 for white blood cell count. Glucose is not above the limit of 100 mg/dl and therefore doesn’t contribute to the score. For creatinine, add [(1.25-1.15)/0.1]´ 0.078´ 10 or 0.78. For coronary angiogram never done add 0.11´ 10 or 1.1. For the use of one anti-anginal drug add 0.13´ 10 or 1.3 to the score. Summing these yields a total score of 8.31, which translates (S-shaped curve, right vertical axis in Figure 1) to a 4% chance of death, myocardial infarction, or disabling stroke in the next five years.
Example 2 is an otherwise similar patient who smokes, has at least one attack of angina per week, has a systolic blood pressure over 155 mm Hg, uses one additional anti-anginal drug, has a history of myocardial infarction and is a man. As shown in Table 1 this adds (0.60+0.22+0.21+0.13+0.14+0.16)´ 10 or 14.6 to the score of 8.31 for the above female patient. According to Figure 1, this patient’s total score of 22.91 implies a 16% chance of death, myocardial infarction, or disabling stroke in five years.
Example 3, if the patient in example 2 also had non-insulin dependent diabetes with a blood glucose of 200 mg/dl, a further 0.13´ 10 for the presence of diabetes and [(200-100)/10]´ 0.032´ 10 or 3.2 for blood glucose must be added. The total score of 22.91+1.3+3.2 or 27.41 translates (see Figure 1) to a 24% chance of death, myocardial infarction or disabling stroke in five years.
Related articles
- This Week In The BMJ Published: 13 October 2005; BMJ 331 doi:10.1136/bmj.331.7521.0
- Research Published: 06 August 2009; BMJ 339 doi:10.1136/bmj.b3058
- Clinical Review Published: 29 May 2003; BMJ 326 doi:10.1136/bmj.326.7400.1185
- Primary Care Published: 07 April 2005; BMJ 330 doi:10.1136/bmj.38398.408032.8F
- PRIMARY CARE Published: 24 March 2005; BMJ doi:10.1136/bmj.38398.408032.8F
- Research Published: 20 January 2010; BMJ 340 doi:10.1136/bmj.b5606
- Paper Published: 14 July 2001; BMJ 323 doi:10.1136/bmj.323.7304.75
- Research Published: 14 November 2008; BMJ 337 doi:10.1136/bmj.a2240
See more
- Stroke: Take test for genetic variant to ensure clopidogrel works for prevention, says NICEBMJ May 19, 2023, 381 p1146; DOI: https://doi.org/10.1136/bmj.p1146
- David Oliver: What the plan for social care omittedBMJ September 10, 2021, 374 n2227; DOI: https://doi.org/10.1136/bmj.n2227
- Stroke: “striking reductions” are seen in number of people with symptoms seeking helpBMJ April 06, 2020, 369 m1406; DOI: https://doi.org/10.1136/bmj.m1406
- NICE recommends implantable monitor to identify atrial fibrillation after strokeBMJ January 14, 2020, 368 m133; DOI: https://doi.org/10.1136/bmj.m133
- Thrombectomy can be considered up to 24 hours after onset of stroke, says NICEBMJ November 23, 2018, 363 k4995; DOI: https://doi.org/10.1136/bmj.k4995
Cited by...
- Machine learning approaches improve risk stratification for secondary cardiovascular disease prevention in multiethnic patients
- White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry)
- A 10-year prognostic model for patients with suspected angina attending a chest pain clinic
- Field Synopsis of the Role of Sex in Stroke Prediction Models
- Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model
- Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study
- Development of a composite model derived from cardiopulmonary exercise tests to predict mortality risk in patients with mild-to-moderate heart failure
- Simple Integer Risk Score to Determine Prognosis of Patients With Hypertension and Chronic Stable Coronary Artery Disease
- COURAGE or FAME...? Who should have percutaneous coronary intervention in stable coronary artery disease?
- A 'Polypill' Aimed At Preventing Cardiovascular Disease Could Prove Highly Cost-Effective For Use In Latin America
- 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
- 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
- Management of stable angina: summary of NICE guidance
- Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery
- Improving Global Vascular Risk Prediction With Behavioral and Anthropometric Factors: The Multiethnic NOMAS (Northern Manhattan Cohort Study)
- Five year prognosis in patients with angina identified in primary care: incident cohort study
- COURAGE to change practice? Revascularisation in patients with stable coronary artery disease
- Do patients with angina alone have a more benign prognosis than patients with a history of acute myocardial infarction, revascularisation or both? Findings from a community cohort study
- States, rates and traits: prognosis research and chronic stable angina
- Incremental prognostic value of the exercise electrocardiogram in the initial assessment of patients with suspected angina: cohort study
- Predictors of Outcome and the Lack of Effect of Percutaneous Coronary Intervention Across the Risk Strata in Patients With Persistent Total Occlusion After Myocardial Infarction: Results From the OAT (Occluded Artery Trial) Study
- Presentation of stable angina pectoris among women and South Asian people
- Prognosis of stable angina pectoris: why we need larger population studies with higher endpoint resolution
- Stable angina who needs revascularisation?
- The Year in Epidemiology, Health Services Research, and Outcomes Research
- Risk Scoring for Patients with Stable Angina
- Can risk score models help in reducing serious outcome events in patients with stable angina?